IQVIA Holdings Inc. (NYSE:IQV – Get Free Report) insider Eric Sherbet sold 4,446 shares of IQVIA stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $278.83, for a total value of $1,239,678.18. Following the completion of the sale, the insider directly owned 24,989 shares in the company, valued at approximately $6,967,682.87. The trade was a 15.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
IQVIA Stock Down 1.2%
Shares of IQV opened at $271.11 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83. The stock has a market capitalization of $44.68 billion, a price-to-earnings ratio of 32.94, a price-to-earnings-growth ratio of 2.44 and a beta of 1.16. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $284.50. The business’s 50 day simple moving average is $267.67 and its 200-day simple moving average is $211.75.
IQVIA (NYSE:IQV – Get Free Report) last posted its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The firm had revenue of $4.43 billion during the quarter, compared to analyst estimates of $4.37 billion. During the same period last year, the firm posted $3.00 earnings per share. IQVIA’s revenue for the quarter was up 8.0% compared to the same quarter last year. As a group, equities analysts expect that IQVIA Holdings Inc. will post 11.53 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on IQV. Barclays boosted their target price on shares of IQVIA from $275.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. HSBC increased their price target on shares of IQVIA from $280.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, September 1st. UBS Group initiated coverage on IQVIA in a research report on Wednesday, September 30th. They issued a “buy” rating and a $345.00 price target for the company. Truist Financial lifted their price target on IQVIA from $329.00 to $346.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Finally, Mizuho boosted their price objective on IQVIA from $275.00 to $300.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $294.21.
Get Our Latest Report on IQVIA
IQVIA Company Profile
IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.
Featured Articles
- Five stocks we like better than IQVIA
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
